West Michigan Rheumatology was one of the original investigational sites for Enbrel - the first biologic approved for use in psoriatic arthritis. We also performed the early phase 1 and 2 studies of Brodalumab in rheumatoid arthritis.
AMVISION-2 is a study of the effectiveness and safety of Brodalumab (a monoclonal antibody directed against interleuken-17) in patients with Psoriatic Arthritis. Our participation evaluating this novel therapeutic target is an extension of this series of investigations and shows our committment to helping explore the possible conditions that could potentially benefit from targeted biologic therapy, including psoriatic arthritis.
IL-17 is produced by T-cells and induces expression of IL-6, IL-8 and surface ICAM-1 by fibroblasts as well as T cell proliferation. Interleukin 17 is an emerging therapeutic target in the rheumatic diseases.
Preliminary results of previous studies of Brodalumab in Rheumatoid Arthritis have established a foundation of safety experience.
A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Martin DA, Churchill M, Flores-Suarez L, Cardiel MH, Wallace D, Martin R, Phillips K, Kaine JL, Dong H, Salinger D, Stevens E, Russell CB, Chung JB. Arthritis Res Ther. 2013 Oct 25;15(5):R164. doi: 10.1186/ar4347.
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar A, Newmark R, Feng J, Erondu N, Nirula A. N Engl J Med. 2014 Jun 12;370(24):2295-306. doi: 10.1056/NEJMoa1315231.
Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. Viswanathan HN, Chau D, Milmont CE, Yang W, Erondu N, Revicki DA, Klekotka P. J Dermatolog Treat. 2014 Jul 31:1-5.
Enrollment is now closed for the phase 3 study that evaluates the effect of brodalumab on psoriatic arthritis. To paricipate one must be 18 yo, have psoriatic arthritis for > 6 months, have at least 3 tender and 3 swollen joints and have an active psoriatic skin lesion. This is a 6 months study followed by a 2 year open label extension study. You can learn more at clinicaltrials.gov.
Want to learn more?
We have only shared a brief overview of our current research projects. If you are interested in learning more about participation, please contact our research coordinator via email using the form below. She would be happy to provide further information on specific studies via email and follow up with you on the phone to answer your questions about the details of participation. You may also reach her by calling 616.459.8088.